CRSTI
7777 Forest Lane
Suite C-742
Dallas, TX 75230
972-566-6820
fax: 972-566-8524
info@crsti.org
A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal (GI) safety and tolerability of myfortic® and MMF (Cellcept®) when administered in combination with calcineurin inhibitors (CNI) in renal transplant recipients experiencing gastrointestinal intolerance (MyGAIN)
Sponsor: Novartis
Investigator: Bekir Tanriover, MD
Research Coordinator: Tina Worley, RN, BSN
Designated Site: Dallas Transplant Institute
The purpose of this study is to learn more about the experiences and symptoms associated with taking immunosuppressants following renal transplant surgery by switching approximately half of the patients to a delayed release formulation that is developed to alleviate GI symptoms.